Association of chemotherapy dose intensity and age with outcomes in patients with Ewing's family sarcoma
Asia-Pacific Journal of Clinical Oncology · 2025
DOI: 10.1111/ajco.13998 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, 2025. Verfasst von Danielle Klingberg und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Prince of Wales Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Sarcoma, Ewing, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Ewing's family sarcoma (EFS) is an aggressive malignancy with a peak incidence in adolescents. Multimodal treatment involves surgery and/or radiotherapy, and chemotherapy typically with VDC/IE (vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide). There is a paucity of data for the treatment of adults, with protocols extrapolated from the pediatric setting. This study aimed to assess patterns of care, chemotherapy tolerability across age groups, and outcomes from four Australian sarcoma centers.
Methods
ANZSA ACCORD sarcoma database and medical records were used to identify and collect data of patients aged ≥ 10 years with EFS who received VDC/IE between 2010 and 2020. Survival outcomes were analyzed based on chemotherapy received dose intensity (RDI). Clinical predictors of RDI were explored using logistic regression.
Results
Of 146 patients with EFS, 76 received VDC/IE. The majority had localized disease (65%). Seventy‐one percent completed scheduled chemotherapy, with some requiring dose reduction (29%), delay > 7 days (65%), or cycle omission (4%). Hematological toxicity was the main reason for dose reduction/delay. Fifty‐seven percent patients achieved an acceptable RDI ≥85%. Compared to those aged 10–19, the odds ratio for acceptable RDI aged 40–59 was 0.20 (95% CI 0.04−0.86, p = 0.04). RDI was an independent prognostic factor for overall survival, after accounting for age, gender, Ewing's type, primary site, and stage (adjusted HR 0.25 [95% CI 0.10−0.63], p = 0.004).
Conclusion
Survival outcomes in EFS were associated with chemotherapy RDI. Older adults more commonly required dose reduction or early cessation of treatment due to toxicity. VDC/IE chemotherapy should be carefully tailored in adults > 40 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Prince of Wales Hospital, Sydney, New South Wales, Australia.
- Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
- Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.
- NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
- Department of Medical Oncology, The Kinghorn Cancer Centre, Sydney, New South Wales, Australia.
ORCID-Profile: Peter Grimison, Yeh Chen Lee
Zitieren
APA
Klingberg, D., Bae, S., Zhou, D. D., Sim, H. W., Cai, R., Anazodo, A., Grimison, P., Lewis, C., & Lee, Y. C. (2025). Association of chemotherapy dose intensity and age with outcomes in patients with Ewing's family sarcoma. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.13998
Vancouver
Klingberg D, Bae S, Zhou DD, Sim HW, Cai R, Anazodo A, et al. Association of chemotherapy dose intensity and age with outcomes in patients with Ewing's family sarcoma. Asia-Pacific Journal of Clinical Oncology. 2025. doi:10.1111/ajco.13998
BibTeX
@article{Klingberg2025,
author = {Klingberg, Danielle and Bae, Susie and Zhou, Deborah Di-Xin and Sim, Hao-Wen and Cai, Ruilin and Anazodo, Antoinette and Grimison, Peter and Lewis, Craig and Lee, Yeh Chen},
title = {Association of chemotherapy dose intensity and age with outcomes in patients with Ewing's family sarcoma},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2025},
doi = {10.1111/ajco.13998}
}
EUVIMED